INBRX-106

INBRX-106 · Inhibrx Biosciences

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for INBRX-106, covering 2025-12-18 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC [Phase 2, Phase 3]